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Industrial journalists are always intrigued to
be shown manufacturing processes (from
China Clay, Wedgewood, and Pilkington
through to wire ropes, tyres, gold mines and
coffee farms). 
The whole spectrum of factory work
involves so much - from shift work patterns,
(women with children liking night work as
they see the children home from and also to
school); to machine layouts, flow lines, and
dispatch. (IBM assembling PC's in the box
at its Greenock site, needing  minimal pack-
aging before shipment.) 
It gets down to those curious small details
where time and motion evolve from the
work. Witness the fab which left its machine
covers off.  “These are conventional, not for
safety, and we can change the machine
operation more quickly this way.”
So, in all that appears on nanotechnology,
its materials and devices, the more inter-
esting becomes speculation on how these
nanofabs or labs, or factories of the future
will operate. 
Presumably the industry, semiconductor,
pharmaceutical, etc will impose its own
traditional ‘good, bad and ugly’ into its
nanosector. Though perhaps material
demands may enforce an overall, major
rethink, just as bigger wafers have made
for a change in systems and have still
proved hard, despite theory, to bring into
real profitability.
It seem unlikely that nano manufacturers
will make use of those once-forecast auto-
mated 'lights out' factories. Instead, work
still seems to be the domain of humans,
albeit it shifts from continent to continent,
pursuing tax breaks, markets or cheap,
educated labour.
It is open to speculation whether nano
manufacture will become the domain of
the automation sector, or if some new
niche is springing up where an overview
expertise will play a part.
Take Bayer Technology Services, claiming
more than 7,000 man years of unique
know-how in process management, and
known as a a vertical & horizontal automa-
tion integrator in the chemical/pharma-
ceutical industries.  It has been making
this expertise available to non-Bayer cus-
tomers. Simultaneously, its expertise is
also increasingly flowing into development
departments of automation system mak-
ers, such as Siemens, Endress & Hauser or
Werum. 
Bayer’s Norbert Kuschnerus, head of the
Process Management Technology division
talks of ‘the 360o of process management’
and points to the fact that process indus-
try customers and automation system
manufacturers ‘increasingly focus on core
business, leaving a know-how gap for
solution providers, whose inter-discipli-
nary skills make them the contact for both
sides, to boost profitability and competi-
tiveness of production facilities.’
Looks as if there's an nanotechnology
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